SHIONOGI, INC.
FLORHAM PARK, NJ

Company Overview Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 139-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease. . Shionogi's mission is to supply the best possible medicines to protect the health and well-being of the patients we serve. With over 50 years of anti-infective research experience, Shionogi has helped to revolutionize the development of anti-bacterial and anti-viral treatments. As bacteria, pathogens, and other viruses adapt to resist existing treatments—causing millions of untreatable infections around the world—Shionogi is pursuing the development of novel treatments to combat this evolving threat. Shionogi, both itself and through innovative alliances, is also pursuing the development of new treatments in other areas of high medical need, including inflammatory pain, neuropathic pain, Alzheimer’s disease, and ADHD. At Shionogi Inc., we’re intensely focused on developing and commercializing the scientific breakthroughs emerging from our research laboratories in Japan as well as discoveries of our strategic alliance partners. We couple our innovative discovery base with capabilities to advance drug candidates rapidly from lab to clinic to patient, forming, where appropriate, bold new partnerships to accelerate and amplify the availability of these new medications to patients around the world. In 1878, Gisaburo Shiono, Sr. founded the company that became Shionogi & Co., Ltd. Still located on the original site in Osaka, Japan, today’s Shionogi retains its entrepreneurial spirit while having the resources of a fully integrated pharmaceutical company serving patients worldwide. Our research scientists have discovered therapeutics including naldemedine, rosuvastatin, and dolutegravir, and are currently working on many more potential future products. In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in Atlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients. In 2017, Shionogi Inc. gained approval of Symproic , the first medicine both discovered and globally developed by Shionogi. Shionogi Inc. now has a development organization capable of conducting multiple simultaneous late-stage clinical programs and submitting new drug application (NDA) filings worldwide, and we are now establishing the commercial capabilities to effectively bring these medicines to the appropriate patients. Shionogi Leadership Team The Shionogi Inc. leadership team has decades of combined pharmaceutical and industry experience in developing and commercializing therapeutics. Since 2011, when Shionogi Inc. was established in the U.S., our leadership team has focused on bringing the benefits of Shionogi's small molecule drug innovations to U.S. patients through our own efforts and through multiple inventive collaborations. During this period, Shionogi Inc. gained our first two New Chemical Entity (NCE) approvals while reshaping our business around our science-based heritage and core areas of infectious diseases and pain. Dr. Takayuki Yoshioka joined Shionogi in 1990 in Osaka, Japan and was responsible for the company’s pharmaceutical research in oncology. In his nearly 30 year tenure with Shionogi, Dr. Yoshioka has led the organization in multiple capacities including global development, global quality assurance, pharmacovigilence, and regulatory management. In his most recent role, Dr. Yoshioka served as Senior Executive Officer and Senior Vice President for the Supply Chain Management division. In that role, he was responsible for the worldwide management of Shionogi’s global supply including, procurement for manufacturing, manufacturing strategy and import/export oversight. Dr. Yoshioka also served as Chair of both the global supply, quality, manufacturer and CMC committee and the global sales and operations committee. Prior to joining Shionogi, Dr. Yoshioka gained accolades as a visiting scientist in the Virology Laboratory with the American Red Cross and was a visiting fellow in the Laboratory of Molecular Virology of the National Institutes of Health, National Cancer Institute. Dr. Yoshioka holds his Ph.D. from the Osaka University Medical School and a Master's Degree from the University of Tsukuba Medical School. Mr. Hara joined Shionogi Inc. in July 2010, as Executive Vice President and Chief Financial Officer. Mr. Hara originally joined Shionogi & Co., Ltd. based in Japan in 1995 and since that time has held a variety of positions with growing responsibilities in commercial, financial planning & analysis, accounting, taxes, treasury, internal controls, business development support, and other corporate functions at the Shionogi group companies on a global basis. Mr. Hara began his career with Shionogi as a sales representative in Japan, then moved to the U.S. in 2006 to serve as Director of Accounting and Finance at Shionogi USA Inc. where he was responsible for a broad spectrum of financial functions and various administrative roles. During his time with Shionogi USA Inc., he also played a key global role to liaise between Japan and the U.S., supporting R&D and business functions. Mr. Hara also served as director of the board and held senior leadership roles for other Shionogi group entities. Gary Dickinson joined Shionogi Inc. in October 2011 and leads Shionogi’s Human Resources function in the U.S. Prior to joining Shionogi Inc., Gary had over 25 years of Senior HR experience gained in large corporate companies such as Bristol Myers Squibb and American Express plus valuable experience gained in helping build several successful mid-size companies such as The Medicines Company. Gary has also had CEO experience at Universal WorldEvents, a pharmaceutical meeting and event planning company. His international and broad generalist HR management experience in the Consumer and Pharma sides of the Life Sciences industry give him a unique background to have a significant influence at Shionogi Inc.